COVAXIN booster dose shows promising results
New Delhi, 8/1: COVAXIN® (BBV152) booster dose study shows Promising Results • The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated long-term safety with no serious adverse events. • 6 months after receipt of the second COVAXIN® dose: o Durable neutralising, T and B cell responses detected, which suggests good immune memory responses and long-term…
